.jpg)
IDD Products & Services
Explore YBL-IDD's New Approach-based Methodologies (NAM)-based product solutions including human induced pluripotent stem cells(iPSCS) and Primary cells
Integrated Drug Discovery: Human Cellular Models, Advanced In Vitro Systems & Preclinical CRO Services
IDD Products
YBL provides physiologically relevant human cell models and culture medium engineered to enhance translational fidelity in preclinical discovery and compound screening. The portfolio features isogenic human primary skin cells—including Normal Human Epidermal Keratinocytes (NHEK), Epidermal Melanocytes (NHEM), and Dermal Fibroblasts (NHDF)—paired with dedicated cell expansion kits containing optimized growth media to ensure reliable viability and phenotype retention. Expanding advanced New Approach Methodologies (NAMs), YBL also delivers high-performance human iPSC-derived functional lineages, specifically YBLiCardio (cardiomyocytes) and YBLiHepato (hepatocytes), providing researchers with robust, physiologically predictive platforms for disease modeling, phenotypic screening, and early safety pharmacology.
IDD Services
YBL delivers integrated preclinical contract research services designed to advance discovery workflows from target identification through mechanistic validation. Our capabilities include custom cell line generation and comprehensive characterization, spanning primary skin cell isolation directly from human tissues, somatic reprogramming of donor blood-derived PBMCs into human iPSCs, and directed differentiation into functional downstream lineages. To replicate native tissue architecture, YBL engineers tailored in vitro model systems—including advanced co-cultures, 3D spheroids, organoids, and microfluidic organ-on-chip platforms supported by specialized strategic collaborations—coupled with readout-driven assay biology services. Underpinning every project is our ISO/IEC 27001 certification, providing rigorous data governance, airtight IP confidentiality, and institutional data security to safeguard partner intellectual property and ensure complete regulatory-grade data integrity throughout every phase of collaboration.
